logo image
search icon
Global Clinical Trial Planning and Design Services Market

Clinical Trial Planning and Design Services Market Size, Share & Trends Analysis Report By Trial Phase, By Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, Other Therapeutic Areas), By Service, By Region, And by Segment Forecasts, 2024-2031

Report ID : 1452 | Published : 2024-04-15 | Pages: 180 | Format: PDF/EXCEL

The Clinical Trial Planning and Design Services Market Size is predicted to reach at an 8.90 % CAGR during the forecast period for 2024-2031.

Key Industry Insights & Findings from the Report:

  • Due to advances in research and medical technology, clinical trials are becoming increasingly complex. This complexity requires specialized expertise in test planning and design to ensure efficiency and compliance with regulatory standards.
  • The globalization of clinical research has increased as pharmaceutical and biotech companies seek access to diverse patient populations and healthcare systems. Clinical trial planning services are essential to avoid the challenges of conducting trials in multiple geographies.
  • North America dominated the market and accounted for a revenue share of global revenue in 2023.
  • The increasing reliance on technology and electronic data collection in clinical research raises concerns about data security and patient privacy. Strict data protection regulations can complicate the planning and design of clinical trials.

clinical trial planning

The clinical trial is a protocol that studies new treatments and tests and checks their effects on human health. The clinical trial planning and design services offer data accuracy, adaptability, consistency, and compliance to clinical studies. Pharmaceutical companies use clinical trial planning and design services during the drug development process or molecular analysis of generics and biosimilars.

The factors such as increasing use of clinical trial management services, adoption of advanced medical technologies, and rising government investments for research and development of clinical trial protocols are expected to boost the market growth over the forecast period. Furthermore, increased R&D expenditure by the pharma and biotech companies and the rising prevalence of chronic and infectious diseases are fueling the growth of the clinical trial planning and design services market.

Leading players are emphasizing on global expansion in order to gain a huge market share. For instance, in Sept 2022, Cytel Inc.'s business expanded across the Asia-Pacific area (APAC). This makes Cytel's existing biometrics and advanced statistical solutions more accessible to APAC biotech and biopharma enterprises. Cytel now has offices in Australia, Shanghai, Beijing, and Singapore, with ambitions to grow into Seoul and Tokyo in the future. This expansion is the latest move in Cytel's mission to provide advanced analytics capabilities to drug developers worldwide.However, the high cost of devices with advanced technologies and poor reimbursement policies may downscale the market growth during 2020-2030.

Market Segmentation

The clinical trial planning and design services market is segmented based on trial phases, therapeutic areas, services, and regions. The Trial Phases segment is divided into Phase I, Phase II, Phase III, and Phase IV. Based on the therapeutic area, the market is divided into oncological disorders, cardiovascular disorders, inflammatory disorders, neurological disorders, and other therapeutic areas. The oncological disorders segment is the fastest-growing segment of the clinical trial planning and design market due to the rising prevalence of cancer. Furthermore, the neurological disorders segment is anticipated to boost the market, owing to the rise in neurology clinical trials. By Services, the market is segmented into statistical analysis plan, eCRF, site identification and selection, medical writing, and other services.

Based on the region, the clinical trial planning and design services market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. In 2021, North America dominated the clinical trial planning and design services market. The large share of the North American regional segment can be attributed to the increasing number of pharmaceutical companies, rising adoption of advanced medical technologies, and high clinical R&D investments by the government.

Some of the key players operating in the clinical trial planning and design services market are Atlantia Clinical Trials, PharmaLex, Emergo UL, Cytel, Health Policy Associate, CD BioSciences, LLX Solutions, SGS, ADM Korea, McDougall Scientific, ClinAsia, BioPoint, IQVIA, PPD, Inc., Veristat, LLC, Clinical Accelerator, Allied Clinical Management GmbH, Parexel International Corporation, Pepgra, WIRB-Copernicus Group, and other.

Competitive Landscape:

  • Atlantia Clinical Trials
  • PharmaLex
  • Emergo UL
  • Cytel
  • Health Policy Associate
  • CD BioSciences
  • LLX Solutions
  • SGS
  • ADM Korea
  • McDougall Scientific
  • ClinAsia
  • BioPoint
  • IQVIA
  • PPD, Inc.
  • Veristat, LLC
  • Clinical Accelerator
  • Allied Clinical Management GmbH
  • Parexel International Corporation
  • Pepgra
  • WIRB-Copernicus Group
  • Other Prominent Players

Clinical Trial Planning and Design Services Market Report Scope

 

Report Attribute

Specifications

Growth Rate CAGR

CAGR of 8.90 % from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

Trial Phase, Therapeutic Area, Service

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Creative Biolabs, Medicago Inc., iBio, ICON, EEA Consulting Engineers, Kentucky BioProcessing, Inc., Baiya Phytopharm and Protalix Biotherapeutics.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Clinical Trial Planning and Design Services Market Snapshot

Chapter 4. Global Clinical Trial Planning and Design Services Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Trial Phases Estimates & Trend Analysis

5.1. By Trial Phases & Market Share, 2019 & 2031

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Trial Phases:

5.2.1. Phase I

5.2.2. Phase II

5.2.3. Phase III

5.2.4. Phase IV

Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis

6.1. By Therapeutic Area & Market Share, 2019 & 2031

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Therapeutic Area:

6.2.1. Oncological Disorders

6.2.2. Cardiovascular Disorders

6.2.3. Inflammatory Disorders

6.2.4. Neurological Disorders

6.2.5. Other Therapeutic Areas

Chapter 7. Market Segmentation 3: By Service Estimates & Trend Analysis

7.1. By Service & Market Share, 2019 & 2031

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Service:

7.2.1. Statistical Analysis Plan

7.2.2. eCRF

7.2.3. Site Identification and Selection

7.2.4. Medical Writing

7.2.5. Other Services

Chapter 8. Clinical Trial Planning and Design Services Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Trial Phases, 2019-2031

8.1.2. North America Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2019-2031

8.1.3. North America Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Service, 2019-2031

8.1.4. North America Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

8.2. Europe

8.2.1. Europe Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Trial Phases, 2019-2031

8.2.2. Europe Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2019-2031

8.2.3. Europe Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Service, 2019-2031

8.2.4. Europe Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Trial Phases, 2019-2031

8.3.2. Asia Pacific Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2019-2031

8.3.3. Asia-Pacific Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Service, 2019-2031

8.3.4. Asia Pacific Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

8.4. Latin America

8.4.1. Latin America Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Trial Phases, 2019-2031

8.4.2. Latin America Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2019-2031

8.4.3. Latin America Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Service, 2019-2031

8.4.4. Latin America Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Trial Phases, 2019-2031

8.5.2. Middle East & Africa Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2019-2031

8.5.3. Middle East & Africa Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by Service, 2019-2031

8.5.4. Middle East & Africa Clinical Trial Planning and Design Services Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Atlantia Clinical Trials

9.2.2. PharmaLex

9.2.3. Emergo UL

9.2.4. ICON plc

9.2.5. Cytel

9.2.6. Health Policy Associate

9.2.7. CD BioSciences

9.2.8. LLX Solutions

9.2.9. SGS

9.2.10. ADM Korea

9.2.11. McDougall Scientific

9.2.12. ClinAsia

9.2.13. BioPoint

9.2.14. IQVIA

9.2.15. PPD, Inc.

9.2.16. Veristat, LLC

9.2.17. Clinical Accelerator

9.2.18. Allied Clinical Management GmbH

9.2.19. Parexel International Corporation

9.2.20. Pepgra

9.2.21. WIRB-Copernicus Group

9.2.22. Afortiori Development Ltd

9.2.23. Celerion

9.2.24. CCS (Cardiovascular Clinical Sciences)

9.2.25. MCRA

9.2.26. dicentra

9.2.27. DOT WORLD (Japan)

9.2.28. Other Prominent Players

 

Market Segmentation of Clinical Trial Planning and Design Services Market

Clinical Trial Planning And Design Services Market Revenue, by Trial Phases, 

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

clinical trial planning

Clinical Trial Planning And Design Services Market Revenue, by Therapeutic Area, 

  • Oncological Disorders
  • Cardiovascular Disorders
  • Inflammatory Disorders
  • Neurological Disorders
  • Other Therapeutic Areas

Clinical Trial Planning And Design Services Market Revenue, by Service,

  • Statistical Analysis Plan
  • eCRF
  • Site Identification and Selection
  • Medical Writing
  • Other Services

Clinical Trial Planning And Design Services Market Revenue, by Region, 

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Clinical Trial Planning And Design Services Market Revenue, by Country, 

  • U.S.
  • Canada

Europe Clinical Trial Planning And Design Services Market Revenue, by Country,

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Clinical Trial Planning And Design Services Market Revenue, by Country, 

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Clinical Trial Planning And Design Services Market Revenue, by Country,

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Clinical Trial Planning And Design Services Market Revenue, by Country, 

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

What is the Global Clinical Trial Planning And Design Services Market Growth?

Atlantia Clinical Trials, PharmaLex, Emergo UL, Cytel, Health Policy Associate, CD BioSciences

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$100000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach